DIA Oligonucleotide-Based Therapeutics Conference
|
|
- Scarlett Black
- 6 years ago
- Views:
Transcription
1 DIA Oligonucleotide-Based Therapeutics Conference North Bethesda MD October 25-27
2 Translating PD Biomarkers From Preclinical Studies to Clinical Trials: MRG-201, an Oligonucleotide Mimic of mir- 29, Inhibits Collagen Expression and Reduces Fibroplasia in Cutaneous Wounds Corrie L. Gallant-Behm, Ph.D. October 26, 2017
3 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. DIA and the DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
4 microrna Therapeutics Regulate Systems Biology to Modify Disease microrna-targeted therapy is focused on disease modification by restoring homeostasis to dysregulated processes micrornas regulate complex biological systems microrna-targeted therapies are intrinsically focused on diseaserelevant pathways microrna therapeutics particularly suited for complex, multigenic disorders
5 Regulating Systems Biology to Modify Disease mir-29 is an Anti-Fibrotic microrna TGF-b + Diseased ECM Inflammation
6 A mir-29 Positive Feedback Loop in Fibrosis Homeostasis Scar Formation Injury mir-29 TGFβ, PDGF EGF IGF Matrix
7 Therapeutic Hypothesis MRG-201 restores homeostasis by modulating the positive feedback loops that maintain the fibrotic phenotype Homeostasis promir-29 TGFβ, PDGF EGF IGF Matrix
8 Reduced mir-29 Has Been Implicated in Multiple Fibrotic Diseases Keloid scar Hypertrophic scar Scleroderma Cardiac fibrosis Pulmonary fibrosis IPF, CTD-associated Liver fibrosis cirrhosis, NASH, viral Kidney fibrosis diabetic nephropathy, IgA Retinal fibrosis, corneal fibrosis
9 mir-29 as a Therapeutic in Cutaneous Fibrosis Keloids Preclinical models mpoc Human Volunteer Wound Repair Hypertrophic Scars Drug Placebo Cutaneous Scleroderma Safety, PK, Target Engagement (PD)
10 Gene Expression Profiling and PD Biomarker Identification Reciprocally regulated genes identified: mir-29b mimic antimir-29 Functional Annotation (GO terms) ECM: Collagen Extracellular matrix Function: Skin development Epidermis development Ectoderm development Cellular homeostasis Adhesion/cell signaling Signal peptide Cell adhesion Cation binding/transport Cell behavior Cell differentiation Apoptosis Structure: Nuclear lumen RNA: RNA processing ncrna processing mrna splicing Helicase
11 P B S 1.9 m g 3.9 m g 7.7 m g 1 g m ir -2 9 m im ic **** 5.5 m m R N A e x p re s s io n (fo ld c h a n g e ) m R N A e x p re s s io n (fo ld c h a n g e ) m R N A e x p r e s s io n (fo ld c h a n g e ) P B S 7.7 m g m g m g m ir -2 9 m im ic C O L 1 A 1 C O L 1 A 2 C O L 3 A 1 C O L 5 A 3 C O L 1 1 A **** P B S 0.4 m g 1 g m ir -2 9 m im ic ****.0 m m R N A e x p re s s io n (fo ld c h a n g e ) 1.5 **** U N T 2 u M 1 0 u M m ir -2 9 m im ic C O L 1 A 2 C O L 3 A 1 ELN F S T L 1 LBR P R IC K L E 1 T G F B 3 C O L 1 A 1 C O L 1 A 2 C O L 3 A 1 M M P 2 T G F B 2 C O L 1 A 1 C O L 1 A 2 C O L 3 A 1 C O L 1 1 A 1 E L N T G F B 2 Regulation of ECM Genes by MRG-201
12 Downregulation of mir-29 and Overexpression of mir-29 Target Genes in Keloids and Skin Scars
13 MRG-201: First-In-Human Phase 1 Study in Healthy Volunteers Four part study: Part A - Incision only, no drug; establish kinetics of expression of PD biomarkers Objectives: Part B Intradermal MRG-201 in intact skin; 6 dose levels ( mg); single administration Part C Intradermal MRG-201 in incised skin; single ascending dose (SAD); 3 dose levels (4, 7, 14 mg) Part D Intradermal MRG-201 in incised skin; multiple ascending dose (MAD); 3x/week for 2 weeks; 3 dose levels (4, 7, 14 mg) Part D4 Intradermal MRG-201 at one end of skin incision; 3x/week for 2 weeks; 14 mg dose level. Biopsy both treated and untreated ends of incision. Primary: Investigate the safety and tolerability of intradermal MRG-201 Secondary: Characterize the pharmacokinetic profile of MRG-201 Exploratory: Pharmacodynamic profile of MRG-201 in skin mir-29 level following incision
14 Clinical Trial MRG Part A: Establish Kinetics of PD Gene Expression mir-29 qpcr Nanostring Incision Biopsy Biopsy RNA Day 1 Day 9 Day 16
15 mir-29 Expression Decreases and mir-29 Direct Target Expression Increases Following Incision mir-29 Quantity Genes significantly regulated in incised vs. intact skin (BH p-value <0.01) n s M F A P 2 m ir -2 9 C o p y N u m b e r P e r C e ll F o ld C h a n g e v s. u n w o u n d e d C O L 3 A 1 C O L 5 A 2 C O L 1 A 2 T G F B 3 M M P 2 F S T L 1 E L N C O L 5 A 3 T G F B 2 N E D D 4 L S N X 2 7 S D C 4 C O L 1 A 1 C O L 1 1 A 1 C Y T L 1 G I M A P 7 P R I C K L E 1 L B R I T G A 3 N U M B 0 U n in c is e d D a y 9 In c is io n D a y 1 6 In c is io n D a y 9 D a y 1 6
16 Parts B/C/D: Safety, Tolerability and PK in Intact Skin and Skin Incisions, PD target engagement Normal healthy volunteers Single and multiple ascending dose (N=3/cohort) mg MRG-201 injected intradermally Part B: Intact skin Safety/tolerability only, no biopsies Part C: Incised skin, single administration Biopsy 24h after treatment for PD Part D: Incised skin, multiple administration (6 doses over 2 weeks) Biopsy 24h after final administration for PD Line or Incision Drug Line or Incision Placebo RESULTS Dosing and follow-up complete All doses well tolerated up to the maximally deliverable dose No significant injection site reactions Low systemic exposure of full length MRG-201 for all subjects with many samples below limit of quantitation Treated skin biopsy biodistribution assessments (dual probe hybridization assay) showed concentrations ranging from 12 to 200 g/g tissue Pharmacodynamic biomarker data demonstrate target engagement with single and multiple administration of MRG-201
17 MRG-201 Mechanistic Proof-of-Concept in Human Incised Skin Evidence of PD activity (mpoc) after single administration of MRG-201 Validation of preclinical PD biomarkers in human incised skin SINGLE DOSE
18 MRG-201 Treatment Significantly Blunts Fibroplasia in Human Incised Skin Multiple Ascending Dose Cohorts D1-D3 D e p th /W id th (m m ) o r A r e a (m m 2 ) p = S a lin e M R G S a lin e M R G S a lin e M R G W id t h D e p th A r e a F ib r o p la s ia
19 MRG-201 Target Engagement Corresponds to Impact on Fibroplasia Multiple Ascending Dose Cohorts D1-D3 * These subjects had no or minimal detectable fibroplasia (<2mm 2 ) in either saline or MRG-201 treated incisions
20 MRG-201 Target Engagement Corresponds to Impact on Fibroplasia Multiple Ascending Dose Cohorts D1-D3
21 mir-29 as a Therapeutic in Cutaneous Fibrosis Keloids Preclinical models mpoc Human Volunteer Wound Repair Hypertrophic Scars Drug Placebo Cutaneous Scleroderma Safety, PK, Target Engagement (PD)
22 MRG-201 Pharmacodyamic Biomarkers Translate to Multiple Fibrotic Indications TGFB2 Nedd4l Prickle1 Faim2 COL5A3 Gimap7 Cacna1g Colec11 ELN Mfap2 COL5A2 COL1A1 COL3A1 COL11A1 TGFB3 Fstl1 COL1A2 Cytl1 MMP2 Sdc4 Snx27 Itga3 Numb Lbr MRG-201 antimir-29 Day 9 Day 16 SSc skin SSc lung IPF lung Mouse skin vs. vehicle Human skin incision vs. unwounded Human disease tissue vs. normal tissue
23 Conclusions MRG-201 represses expression of genes associated with extracellular matrix production MRG-201 PD biomarker genes are conserved across species Endogenous mir-29 and MRG-201 PD biomarker genes are inversely expressed in cutaneous incisions in normal healthy volunteers, indicating a role for mir-29 in fibrosis development/ progression MRG-201 regulates PD biomarkers and reduces fibroplasia in skin incisions, demonstrating mechanistic proof-of-concept MRG-201 has therapeutic potential in reducing cutaneous fibrosis such as keloids, hypertrophic scars, cutaneous scleroderma MRG-201 PD biomarkers are conserved in other diseases including IPF and SSC-ILDs, indicating therapeutic potential in additional fibrotic conditions
Improved Perfusion and Wound Healing in Healthy Pigs with MRG-110, an Inhibitor of microrna-92a
Restoring Biological Harmony for Patients with Debilitating Disease Improved Perfusion and Wound Healing in Healthy Pigs with MRG-11, an Inhibitor of microrna-92a Rusty Montgomery, Ph.D. April 27 th, 218
More informationSmall Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment
Small Molecule Inhibitor of the Wnt Pathway (SM755) as a Potential Topical Scleroderma Treatment Vishal Deshmukh, PhD, Allison Hood, Yusuf Yazici, MD Disclosures Vishal Deshmukh, Ph.D. o Financial disclosure:
More informationGDUFA: 2 ½ years later Impact & Importance
GDUFA: 2 ½ years later Impact & Importance Georgia Hizon Manager, Regulatory Publications Fresenius Kabi USA, LLC Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationOther EU Activities Contributing to Harmonization of Labeling
Other EU Activities Contributing to Harmonization of Labeling Dr Laurent Brassart European Medicines Agency Medical Information Sector DIA Labeling Harmonisation 2011 Workshop October 13-14. 2011 Disclaimer
More informationDisclaimer. Dialogue with a Patient 3/18/2016
Medical Affairs and Scientific Communications 2016 Annual Forum Dialogue with a Patient Bill Wilkins, Co-Founder, Executive Director, Wilkins Parkinsons Foundation March 21-23 Kissimmee, FL Disclaimer
More information3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant
Phase 0 Microdosing Studies with Renin Inhibitors J. Chris Jensen Consultant Speedel Holding Ltd. Basel, Switzerland Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationRegulatory Experience in Reviewing CV Safety for Diabetes
Regulatory Experience in Reviewing CV Safety for Diabetes Drugs Kristina Dunder MD, PhD, Alternate CHMP member MPA, Sweden Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationUncovering the mechanisms of wound healing and fibrosis
Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:
More informationUpdate on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids
Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids Presenter: Pamela A. Pavco, PhD Chief Development Officer RXi Pharmaceuticals
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationDisclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA
Statistical Aspects of Revision of CHMP Bioequivalence Guidelines David Brown MHRA 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter
More informationData retrieval using the new SMQ Medication Errors
Data retrieval using the new SMQ Medication Errors Christina Winter Medical Director Safety Evaluation and Risk Management, GSK Information Day on Medication Errors 20 October 2016 London, UK Disclaimer
More informationElectrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes
Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes Based on Data from the Telemetric and Holter ECG Warehouse (THEW) Initiative Jean-PhiIippe Couderc, PhD Center for Quantitative
More informationPreview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations
Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Judy Harrison, M.D. Chief Medical Officer MedDRA MSSO Information Day on Medication Errors 20 October 2016 London,
More informationPMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight PMDA Perspectives
More informationFood can serve as a non pharmacological control in thorough cardiac safety studies
Food can serve as a non pharmacological control in thorough cardiac safety studies Jorg Taubel MD FFPM Washington 14 th April 2011 Disclaimer The views and opinions expressed in the following PowerPoint
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More informationAnimal Models of Scarring: The Rabbit Ear Model and its Translational Relevance. Thomas A. Mustoe Northwestern University Chicago,IL USA
Animal Models of Scarring: The Rabbit Ear Model and its Translational Relevance Thomas A. Mustoe Northwestern University Chicago,IL USA Important Regulators of Scarring Genetics (racial characteristics,
More informationTranslating New Immune Pathways into Meaningful Medicines
Translating New Immune Pathways into Meaningful Medicines Cantor Fitzgerald 2018 Global Healthcare Conference Sanjay S. Shukla, M.D., M.S., President & CEO October 2, 2018 Forward-Looking Statements The
More informationWeb-based epro: Validation, Equivalence, and Data Quality. Brian Tiplady
Web-based epro: Validation, Equivalence, and Data Quality Brian Tiplady Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not
More information9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience
Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience Judith Creba Head EU Liaison and Policy, DRA Novartis Pharma AG, Switzerland Disclaimer The views
More informationHealing & Repair. Tissue Regeneration
Healing & Repair Dr. Srikumar Chakravarthi Repair & Healing: Are they same? Repair :Regeneration of injured cells by cells of same type, as with regeneration of skin/oral mucosa (requires basement membrane)
More informationSo, My FitBit is Clinical Trial Grade Right? Keith Wenzel Senior Director, Solution Incubator PAREXEL International
So, My FitBit is Clinical Trial Grade Right? Keith Wenzel Senior Director, Solution Incubator PAREXEL International 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationMedDRA Coding Quality: How to Avoid Common Pitfalls
MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationThe Telemetric and Holter ECG Warehouse (THEW) Initiative
The Telemetric and Holter ECG Warehouse (THEW) Initiative Jean-Philippe Couderc, PhD THEW HRFUP- Cardiology University of Rochester Medical Center, NY Mission Statement The objective of the Telemetric
More informationHealthcare Professional Information & Patient Information Leaflet (PL)
New concept for the SmPC/ Healthcare Professional Information & Patient Information Leaflet (PL) Fiona Reekie Director Global Regulatory Affairs Johnson & Johnson Pharmaceuticals Group Disclaimer The views
More informationVicore Pharma AB. Audiocast, October 2, Presentation by Per Jansson, CEO and Ulrike Muscha Steckelings, CSO
Vicore Pharma AB Audiocast, October 2, 2017 1 Presentation by Per Jansson, CEO and Ulrike Muscha Steckelings, CSO FORWARD-LOOKING STATEMENTS This presentation may contain certain forward-looking statements
More informationAbnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9
Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S1A9 Joanna Nikitorowicz-Buniak UCL Division of Medicine Systemic sclerosis
More informationFavorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Ellen M. van der Aar, PhD Galapagos, Mechelen, Belgium L. Fagard, J.
More informationDisclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be
Ending the Myths: Best Practice in Trial Conduct in Latin America Katie Margules Global Vice President Alliance Management Covance Disclaimer The views and opinions expressed in the following PowerPoint
More informationConducting Observational studies in Latin America: Academia, Ethical Committees & Pharmaceutic Industry
Conducting Observational studies in Latin America: Academia, Ethical Committees & Pharmaceutic Industry Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationInterim Results for 6 Months Ended 31 March 2017 and Business Update. 17 th May 2017
Interim Results for 6 Months Ended 31 March 2017 and Business Update 17 th May 2017 Forward-looking Statements Please Note This presentation includes forward-looking statements. These forward-looking statements
More informationGlobal Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA
Global Pediatric Development: We Are Making Progress PMDA Perspective Junko Sato, PhD PMDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter
More informationInhibition of mir-29 protects against cardiac hypertrophy and fibrosis: new insight for the role of mir-29 in the heart
Editorial Page 1 of 6 Inhibition of mir-29 protects against cardiac hypertrophy and fibrosis: new insight for the role of mir-29 in the heart Julie R. McMullen 1,2,3,4,5, Bianca C. Bernardo 1,5,6 1 Baker
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationMechanisms of hepatic fibrogenesis in chronic liver disease
Mechanisms of hepatic fibrogenesis in chronic liver disease JPEMS 2014, Physiopathology Module Corentin Bessy (Nantes) _ Gabrielle Cepella (Amsterdam) _ Charly Gaisne (Angers) _ Gwladys Guilloineau (Angers)
More information10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer
Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials Eckhard Leifke, MD PhD Senior Medical Director Takeda Global Research Development Center, Inc. Presentation
More informationTissue repair. (3&4 of 4)
Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid
More informationRegulatory scientific significance of Japan s ADR relief system
Regulatory scientific significance of Japan s ADR relief system Toshi TOMINGA, Ph.D. Associate Executive Director Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationUnderstanding Root Cause: Pathogenesis of Hepatic Fibrosis
10/1/12 Understanding Root Cause: Pathogenesis of Hepatic Fibrosis Hepatitis C Virus Mild inflammation Inflammation Fibrosis Cirrhosis 1 10/1/12 Non-alcoholic Fatty Liver Disease Steatosis Steatohepatitis
More informationMolecular mechanisms of Fibrosis: Targets of Therapy. John P Iredale University of Edinburgh, UK
Molecular mechanisms of Fibrosis: Targets of Therapy John P Iredale University of Edinburgh, UK Take home messages: The wound healing MFBs of the liver and the hepatic macrophages are key players in progressive
More informationForward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
More informationPaternal exposure and effects on microrna and mrna expression in developing embryo. Department of Chemical and Radiation Nur Duale
Paternal exposure and effects on microrna and mrna expression in developing embryo Department of Chemical and Radiation Nur Duale Our research question Can paternal preconceptional exposure to environmental
More informationAfter this presentation and discussion, the participants should be able to:
Tissue Repair Robert F. Diegelmann, Ph.D. OBJECTIVES After this presentation and discussion, the participants should be able to: 1. Define the biochemical responses to tissue injury 2. Describe the mechanisms
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationIn the treatment of partial and full-thickness chronic wounds TRANSFORM YOUR APPROACH TO HEALING: SIGNAL THE BODY, NOT THE WOUND DERMA
In the treatment of partial and full-thickness chronic wounds TRANSFORM YOUR APPROACH TO HEALING: SIGNAL THE BODY, NOT THE WOUND DERMA It s time to signal a new direction in chronic wound treatment. WHY
More informationvi Preface Table 2 Association of Fibrosis With Types of Injury: Representative Examples
Fibrosis or scar, defined pathologically as inappropriate repair by connective tissue, is increasingly recognized as an important feature of many chronic diseases (Table 1), and as such, represents an
More informationPathology Seminar Series April 24, 2012 Stephanie Schutte, MD
Pathology Seminar Series April 24, 2012 Stephanie Schutte, MD Etiology and Pathogenesis Epidemiology Clinical features Risk factors Radiologic features Radiologic progression IPF Acute exacerbation Gross
More informationExpressional Changes In Growth And Inflammatory Mediators During Achilles Tendon Repair In Diabetic Rats.
Expressional Changes In Growth And Inflammatory Mediators During Achilles Tendon Repair In Diabetic Rats. Paul W. Ackermann, MD, PhD 1, Aisha Ahmed, PhD 1, Nicos Schizas, MD 1, Jian Li, MD, PhD 1, Mahmood
More informationCentralized Procedure
Centralized Procedure CHMP/EMA Overview of CHMP Operations Anthony Humphreys Head of Regulatory, Procedural and Committee Support DIA European Regulatory Affairs Forum 01-02 June 2010 London, UK Disclaimer
More informationA systematic review of overlapping microrna patterns in systemic sclerosis and idiopathic pulmonary fibrosis
REVIEW SSC AND IPF A systematic review of overlapping microrna patterns in systemic sclerosis and idiopathic pulmonary fibrosis Gianluca Bagnato, William Neal Roberts 2, Jesse Roman 3 and Sebastiano Gangemi
More informationGrowth Factors. BIT 230 Walsh Chapter 7
Growth Factors BIT 230 Walsh Chapter 7 3 Definitions Autocrine: a mode of hormone action in which a hormone affects the function of the cell type that produced it. Paracrine: Relating to the release of
More informationRegulatory Aspects - AML & CLL
Regulatory Aspects - AML & CLL Dr Beatriz Flores November 2018 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed
More informationmirna Biomarkers Seena K. Ajit PhD Pharmacology & Physiology Drexel University College of Medicine October 12, 2017
mirna Biomarkers Seena K. Ajit PhD Pharmacology & Physiology Drexel University College of Medicine October 12, 2017 Outline Introduction Circulating mirnas as potential biomarkers for pain Complex regional
More informationImmunology of Wound Healing
Immunology of Wound Healing Danielle Tartar, MD, PhD Assistant Clinical Professor Interim Director of Inpatient Dermatology University of California - Davis Outline Traditional model of wound healing Role
More informationMEK/ERK INHIBITORS: A PROOF-OF-CONCEPT STUDY IN LUNG FIBROSIS
MEK/ERK INHIBITORS: A PROOF-OF-CONCEPT STUDY IN LUNG FIBROSIS Andrew Leask Departments of Dentistry and Physiology and Pharmacology University of Western Ontario Dental Sciences Building London ON Canada
More informationPhase 1 Trial Evaluating MRG-106, a Synthetic Inhibitor of microrna- 155, in Patients with CTCL
EORTC CLTF 2017 meeting on Cutaneous Lymphomas: Insights & Therapeutic Progress Phase 1 Trial Evaluating MRG-106, a Synthetic Inhibitor of microrna- 155, in Patients with CTCL Christiane Querfeld, Francine
More informationScleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis
Scleroderma Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis Incidence 3.7-22.8 cases/million Female:male 5:1 Pulmonary fibrosis common, severe
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationCorporate Presentation
Corporate Presentation June 2018 Kadmon Holdings, Inc. 1 Disclaimers This presentation contains forward looking statements that are based on the beliefs and assumptions and on information currently available
More informationA NEW COLLAGEN ORGANISING TETRAPEPTIDE TO RESTORE SKIN SUPPLENESS
A NEW COLLAGEN ORGANISING TETRAPEPTIDE TO RESTORE SKIN SUPPLENESS v1 COMBATING DIFFERENT SIGNS OF AGING (I) As society becomes evermore youth-focused, the desire to stave off the aging process is stronger
More informationHot Topics in Wound Care 2011
Hot Topics in Wound Care 2011 Thomas E. Serena MD FACS FACHM MAPWCA Founder & Medical Director - Penn North Centers for Advanced Wound Care Chief Medical Officer - SerenaGroup Scientific Director - New
More informationSupplementary Figure 1 IMQ-Induced Mouse Model of Psoriasis. IMQ cream was
Supplementary Figure 1 IMQ-Induced Mouse Model of Psoriasis. IMQ cream was painted on the shaved back skin of CBL/J and BALB/c mice for consecutive days. (a, b) Phenotypic presentation of mouse back skin
More informationBMS : An Anti-Myostatin Adnectin Targeting Duchenne Muscular Dystrophy
BMS-986089: An Anti-Myostatin Adnectin Targeting Duchenne Muscular Dystrophy Leslie Jacobsen, MD Medical Lead GS Tirucherai, M Ahlijanian, F Luo, C Bechtold and the BMS Anti-Myostatin Team PPMD Connect
More informationNACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV
NACFC investor meeting Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC 2017 2 November 2017 Copyright 2017 Galapagos NV Disclaimer This presentation contains forward-looking statements,
More informationSHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT -Seamless drug development paradigms
SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT -Seamless drug development paradigms Claudia Filozof, MD PhD Executive Medical Director Covance Challenges in Clinical Development in NASH
More informationTKM-HBV RNAi Therapeutic for Chronic Hepatitis B Infection
TKM-HBV RNAi Therapeutic for Chronic Hepatitis B Infection Amy Lee, Arbutus Biopharma DIA/FDA Oligonucleotide-Based Therapeutics Conference September 9 Washington, DC Disclaimer The views and opinions
More informationReprogramming through micrornas Stefanie Dimmeler
Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main Reprogramming through micrornas Stefanie Dimmeler Conflict of interest: T2cure GmbH, Miragen Non-coding DNA & RNA and micrornas Human Genome
More information6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia
6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia Raj Long Senior Regulatory Officer Bill & Melinda Gates Foundation Director Dementia Integrated Development UK HMG World
More informationmicrorna Therapeutics Heading Towards the Clinic
GENReports: Market & Tech Analysis microrna Therapeutics Heading Towards the Clinic > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us Topic Introduction and Scope
More informationEuropean Respiratory Society Annual Congress. Presented at: of new drugs for respiratory diseases. Barcelona, Spain, September 7-11, 2013 Page 1
PBI-4050, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: a comparative study with pirfenidone Presented at: Thematic Poster Session:
More informationDrug-Disease Modeling Applied to Drug Development and Regulatory Decision Making in the Type 2 Diabetes Mellitus Arena
Drug-Disease Modeling Applied to Drug Development and Regulatory Decision Making in the Type 2 Diabetes Mellitus Arena Tokyo, Japan, December 8, 2015 Stephan Schmidt, Ph.D. Assistant Professor Center for
More informationEmerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli
More informationHealing and Repair. Dr. Nabila Hamdi MD, PhD
Healing and Repair Dr. Nabila Hamdi MD, PhD 1 ILOs Know the classification of human cells according to their ability for proliferation. Understand the mechanism of cellular regeneration. Identify the types
More informationFor more information about how to cite these materials visit
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-commercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationSerum microrna biomarkers for human DILI
CLEARANCE DRUG bioactivation covalent binding Detoxication GLUCURONIDE SULPHATE DRUG + METABOLITE chemical stress mitochondrial dysfunction apoptosis necrosis hepatocyte hypertrophy hepatocyte hyperplasia
More informationIdiopathic Pulmonary Fibrosis- a degenerative disease in need of a regenerative solution
Idiopathic Pulmonary Fibrosis- a degenerative disease in need of a regenerative solution Dan Chambers Queensland Lung Transplant Service, The Prince Charles Hospital School of Medicine, The University
More informationBRIDGE THE GAP A Human Pathways Approach to Disease Research
BRIDGE THE GAP A Human Pathways Approach to Disease Research BIOMED 21 Brussels December 8 th, 2015 Brigitte Landesmann Systems Toxicology Unit and EURL ECVAM Institute for Health and Consumer Protection
More informationSafety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies
Safety, PK and PD of ARRY502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies L. Burgess*, L. Anderson, C. Nugent, N. Klopfenstein, C. Eberhardt, L. Carter, C. Kass, S. RojasCaro,
More informationCells & Tissues. Chapter 3
Cells & Tissues Chapter 3 Cell Theory Cell is structural and functional unit of life Activity of an organism is dependent upon its cells Principle of Complementarity functions of cells are dependent upon
More informationASSESSMENT OF THE EFFECTS OF GLPG1690 IN IDIOPATHIC PULMONARY DISEASE (IPF) PATIENTS USING FUNCTIONAL RESPIRATORY IMAGING (FRI)
ASSESSMENT OF THE EFFECTS OF GLPG1690 IN IDIOPATHIC PULMONARY DISEASE (IPF) PATIENTS USING FUNCTIONAL RESPIRATORY IMAGING (FRI) B. MIGNOT, W. VOS, C. VAN HOLSBEKE, M. LANCLUS, J. DE BACKER, A. FIEUW, P.
More informationSupplemental Figure S1. PLAG1 kidneys contain fewer glomeruli (A) Quantitative PCR for Igf2 and PLAG1 in whole kidneys taken from mice at E15.
Supplemental Figure S1. PLAG1 kidneys contain fewer glomeruli (A) Quantitative PCR for Igf2 and PLAG1 in whole kidneys taken from mice at E15.5, E18.5, P4, and P8. Values shown are means from four technical
More informationTITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression
AD Award Number: W81XWH-07-1-0253 TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression PRINCIPAL INVESTIGATOR: Pal Gooz, M.D. CONTRACTING ORGANIZATION: Medical
More informationRXi Pharmaceuticals. Bio Investor Forum San Francisco, CA NASDAQ: RXII. October 21, Property of RXi Pharmaceuticals
RXi Pharmaceuticals NASDAQ: RXII Bio Investor Forum San Francisco, CA October 21, 2015 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDisclosures. Outline. Extracellular Vesicles in Fatty Liver Disease. From Contributors to disease pathogenesis to novel biomarkers
Extracellular Vesicles in Fatty Liver Disease From Contributors to disease pathogenesis to novel biomarkers Ariel Feldstein, M.D. Professor of Pediatrics Chief, Division of Pediatric Gastroenterology Hepatology
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationשינויים מולקולאריים ומבניים באי ספיקת לב אפשרויות לטיפול עתידני
שינויים מולקולאריים ומבניים באי ספיקת לב אפשרויות לטיפול עתידני פרופ יהונתן ליאור 1 Braunwald s Heart Disease 8th Edition Chapter 21 Mechanisms of Cardiac Contraction and Relaxation Chapter 22 Pathophysiology
More informationSCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston
SCLERODERMA 101 Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston TYPES OF SCLERODERMA Localized versus Systemic Two Kinds of Scleroderma Localized Scleroderma Morphea Linear
More information4th Symposium E.G.I.D Liver, Diabetes and Cardiovascular Risks
29th 30th November 2016 in Lille Grand Palais 4th Symposium E.G.I.D Liver, Diabetes and Cardiovascular Risks Teresa Cardoso Delgado finished her PhD in 2009 in the University of Coimbra, Portugal.. In
More informationSupplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier
Supplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) in a cohort of patients (N=52) with stage III primary ovarian
More informationExtracellular matrix Basic and translational science: Highlights of the congress
Extracellular matrix Basic and translational science: Highlights of the congress Stephane Heymans, Maastricht University Medical Centre, CARIM, Netherlands Speaker The extracellular matrix modulates cardiac
More informationJournal Club Semmler Lorenz
Beer et al. 2015 - Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration Journal Club 13.11.2017 1 Introduction to
More informationPhase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microrna-155, in CTCL Patients
ASH Annual Meeting, December 11, 2017 Atlanta, Georgia, U.S.A. Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microrna-155, in CTCL Patients Christiane Querfeld, Francine
More informationPost-transcriptional regulation of an intronic microrna
Post-transcriptional regulation of an intronic microrna Carl Novina Dana-Farber Cancer Institute Harvard Medical School Broad Institute of Harvard and MIT Qiagen Webinar 05-17-11 Outline 1. The biology
More informationMicroRNA and Male Infertility: A Potential for Diagnosis
Review Article MicroRNA and Male Infertility: A Potential for Diagnosis * Abstract MicroRNAs (mirnas) are small non-coding single stranded RNA molecules that are physiologically produced in eukaryotic
More informationExpression of insulin-like growth factor-1 receptor in keloid and hypertrophic scar
Experimental dermatology Original article CED Clinical and Experimental Dermatology Expression of insulin-like growth factor-1 receptor in keloid and hypertrophic scar Z.-C. Hu, B. Tang, D. Guo, J. Zhang,
More informationDiscovery of a Small Molecule Inhibitor of the Wnt Pathway as a Potential Disease Modifying Treatment for Knee Osteoarthritis
Discovery of a Small Molecule Inhibitor of the Wnt Pathway as a Potential Disease Modifying Treatment for Knee Osteoarthritis Charlene Barroga, Ph.D., Yong Hu, Ph.D., Vishal Deshmukh, Ph.D., and John Hood,
More informationTopical nanocrystalline silver cream inhibits expression of matrix metalloproteinase-9 in animal models of allergic contact dermatitis.
Topical nanocrystalline silver cream inhibits expression of matrix metalloproteinase-9 in animal models of allergic contact dermatitis. K C Bhol, P J Schechter NUCRYST Pharmaceuticals Inc, Wakefield, MA
More information